Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic

This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections

Year of Publication: 2020
Contained in: European annals of otorhinolaryngology, head and neck diseases Vol. 137, No. 4 (2020), p. 315-317
All journal articles: Search for all articles in this journal
Language: English
Contributors: Herman, P | Author
Vincent, C
Parietti Winkler, C
Loundon, N
Couloigner, V
Tankere, F
Tringali, S
Gallet, P
Papon, J-F
Montava, M
Lavieille, J-P
Charpiot, A
Schmerber, S
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Anosmia
Bell's palsy
COVID-19
Consensus Development Conference
Journal Article
Practice Guideline
Prednisone
SARS-CoV-2
Sudden hearing loss
Additional Keywords: Adrenal Cortex Hormones
Coronavirus Infections
Humans
Otorhinolaryngologic Diseases
Pandemics
Pneumonia, Viral
ISSN: 1879-730X
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 10.09.2020
Date Revised 10.09.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32482571
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1016/j.anorl.2020.04.014
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04183nma a2200829 c 4500
001 NLM311521266
003 DE-601
005 20200911213909.0
007 cr uuu---uuuuu
008 200602s2020 000 0 eng d
024 7 |a 10.1016/j.anorl.2020.04.014  |2 doi 
028 5 2 |a pubmed20n1334.xml 
035 |a S1879-7296(20)30104-6 
035 |a (DE-599)NLM32482571 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Herman, P 
245 1 0 |a Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 10.09.2020 
500 |a Date Revised 10.09.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. 
520 |a This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections 
611 2 7 |a Consensus Development Conference  |2 gnd 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Practice Guideline  |2 gnd 
653 2 |a Adrenal Cortex Hormones  |6 D000305  |a *therapeutic use  |6 Q000627 
653 2 |a Coronavirus Infections  |6 D018352  |a complications  |6 Q000150  |a *drug therapy  |6 Q000188 
653 2 |a Humans  |6 D006801 
653 2 |a Otorhinolaryngologic Diseases  |6 D010038  |a *drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a complications  |6 Q000150  |a *drug therapy  |6 Q000188 
655 7 |a Anosmia  |2 gnd 
655 7 |a Bell's palsy  |2 gnd 
655 7 |a COVID-19  |2 gnd 
655 7 |a Prednisone  |2 gnd 
655 7 |a SARS-CoV-2  |2 gnd 
655 7 |a Sudden hearing loss  |2 gnd 
655 7 |a Adrenal Cortex Hormones  |2 gnd 
689 0 0 |A f  |a Consensus Development Conference 
689 0 1 |A f  |a Journal Article 
689 0 2 |A f  |a Practice Guideline 
689 0 |5 DE-601 
689 1 0 |a Anosmia 
689 1 1 |a Bell's palsy 
689 1 2 |a COVID-19 
689 1 3 |a Prednisone 
689 1 4 |a SARS-CoV-2 
689 1 5 |a Sudden hearing loss 
689 1 |5 DE-601 
689 2 0 |a Adrenal Cortex Hormones 
689 2 |5 DE-601 
700 1 |a Vincent, C 
700 1 |a Parietti Winkler, C 
700 1 |a Loundon, N 
700 1 |a Couloigner, V 
700 1 |a Tankere, F 
700 1 |a Tringali, S 
700 1 |a Gallet, P 
700 1 |a Papon, J-F 
700 1 |a Montava, M 
700 1 |a Lavieille, J-P 
700 1 |a Charpiot, A 
700 1 |a Schmerber, S 
773 0 8 |i in  |t European annals of otorhinolaryngology, head and neck diseases  |g Vol. 137, No. 4 (2020), p. 315-317  |q 137:4<315-317  |w (DE-601)NLM201406012  |x 1879-730X 
856 4 1 |u http://dx.doi.org/10.1016/j.anorl.2020.04.014  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 137  |j 2020  |e 4  |b 21  |c 09  |h 315-317